Paclitaxel-Coated Balloon for the Treatment of Small Vessel In-Stent Restenosis
JACC: Cardiovascular Interventions · 2025
DOI: 10.1016/j.jcin.2025.09.032 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JACC: Cardiovascular Interventions, 2025. Verfasst von Jason Wen und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cedars-Sinai Medical Center, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Angioplasty, Balloon, Coronary, Cardiac Catheters, Cardiovascular Agents, Coated Materials, Biocompatible. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Boston Scientific Corporation.
Abstract (Originalsprache)
BACKGROUND: Treatment of small vessel (SV) coronary artery disease is associated with higher restenosis rates. Drug-coated balloons offer a promising treatment option for stent failure by delivering an antiproliferative drug and avoiding an additional metal implant. However, evidence supporting the use of paclitaxel-coated balloons (PCBs) for in-stent restenosis (ISR) in SVs is limited. OBJECTIVES: The aim of this study was to evaluate the efficacy and safety of PCB vs uncoated balloon angioplasty according to vessel size. METHODS: AGENT IDE (A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis) randomized 600 patients with ISR to treatment with PCBs or uncoated balloons (2:1). This prespecified analysis evaluated the treatment effect of PCBs in SV (reference vessel diameter [RVD] ≤2.75 mm) and large vessel (RVD >2.75 mm) ISR. The primary endpoint of 1-year target lesion failure (TLF) was a composite of target lesion revascularization, cardiac death, and target vessel-related myocardial infarction. RESULTS: Among 597 patients with known angiographic core laboratory-adjudicated vessel size, 56% had SVs (mean RVD 2.4 ± 0.3 mm) and 44% had large vessels (mean RVD 3.1 ± 0.3 mm). One-year TLF was 20.6% vs 22.6% in the SV vs large vessel groups, respectively (HR: 0.92; 95% CI: 0.65-1.31; P = 0.65). PCBs were associated with a 39% relative reduction in TLF compared with balloon angioplasty in patients with SVs (17.7% vs 27.4%; HR: 0.61; 95% CI: 0.37-0.99) and a 43% reduction in patients with large vessels (18.4% vs 30.5%; HR: 0.57; 95% CI: 0.34-0.96). The benefits of PCB use remained consistent, irrespective of vessel size (Pinteraction = 0.88). None of the patients treated with PCBs experienced definite or probable stent thrombosis. CONCLUSIONS: This prespecified subgroup analysis demonstrates that angioplasty with a PCB was associated with consistently reduced rates of 1-year TLF compared with an uncoated balloon in both SV and large vessel ISR patients. (A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis [AGENT IDE]; NCT04647253).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Cedars-Sinai Medical Center, Los Angeles, California, USA. Electronic address: suhail.dohad@cshs.org.
- St. Francis Hospital, Roslyn, New York, USA.
- St. Francis Hospital, Roslyn, New York, USA; Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York, USA; Cardiovascular Research Foundation, New York, New York, USA.
- University of Pittsburgh Medical Center, Central Pennsylvania, Harrisburg, Pennsylvania, USA.
- Lindner Center for Research and Education at Christ Hospital, Cincinnati, Ohio, USA.
Förderung
- Boston Scientific Corporation
Zitieren
APA
Wen, J., Dohad, S., Shlofmitz, R., Moses, J., Bachinsky, W., Rudick, S., Stoler, R., Jefferson, B. K., Nicholson, W., Altman, J., Neupane, S., Croce, K., Shunk, K., Taylor, A., Saybolt, M. D., Diaz, C., Cavalcante, R., Yeh, R. W., & Kirtane, A. J. (2025). Paclitaxel-Coated Balloon for the Treatment of Small Vessel In-Stent Restenosis. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2025.09.032
Vancouver
Wen J, Dohad S, Shlofmitz R, Moses J, Bachinsky W, Rudick S, et al. Paclitaxel-Coated Balloon for the Treatment of Small Vessel In-Stent Restenosis. JACC: Cardiovascular Interventions. 2025. doi:10.1016/j.jcin.2025.09.032
BibTeX
@article{Wen2025,
author = {Wen, Jason and Dohad, Suhail and Shlofmitz, Richard and Moses, Jeffrey and Bachinsky, William and Rudick, Steven and Stoler, Robert and Jefferson, Brian K and Nicholson, William and Altman, John and Neupane, Saroj and Croce, Kevin and Shunk, Kendrick and Taylor, Angela and Saybolt, Matthew D and Diaz, Claro and Cavalcante, Rafael and Yeh, Robert W and Kirtane, Ajay J},
title = {Paclitaxel-Coated Balloon for the Treatment of Small Vessel In-Stent Restenosis},
journal = {JACC: Cardiovascular Interventions},
year = {2025},
doi = {10.1016/j.jcin.2025.09.032}
}
EUVIMED